logo
Plus   Neg
Share
Email

AstraZeneca Says Imfinzi Approved In China For Stage III NSCLC - Quick Facts

AstraZeneca (AZN,AZN.L) announced that Imfinzi has been approved in China for the treatment of unresectable, Stage III non-small cell lung cancer based on the Phase III PACIFIC trial.

The approval of Imfinzi is based on results from the primary analysis of progression-free survival and supported by overall survival from the Phase III PACIFIC trial. Results showed a statistically significant and clinically meaningful OS and PFS benefit for treatment with Imfinzi vs. placebo after concurrent chemotherapy and radiation therapy.

Imfinzi reduced the risk of death by 32% and prolonged the time patients lived without disease progression or death by more than 11 months.

Dave Fredrickson, Executive Vice President, Oncology Business Unit said, "This approval illustrates our long-standing commitment to improving health outcomes in China, where more than one-third of the world's lung cancer diagnoses and deaths occur. As the global standard of care in this curative-intent setting, Imfinzi is an important new option for patients in China."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has unveiled Instagram Reels as its answer to the popular Chinese-owned video app TikTok. The social media giant said in a blog post that Instagram Reels is a new way to create short, entertaining videos on Facebook's photo-sharing app Instagram. Facebook reportedly shut down its TikTok clone Lasso in July, ahead of the launch of Instagram Reels. WD-40 Company recalled about 130,000 units of X-14 Mildew Stain Remover for potential risk of skin irritation, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said pressure can build up inside the bottle and cause it to fall over and leak, posing a risk of skin irritation. Biopharmaceutical company Bristol-Myers Squibb Co. on Thursday reported a loss for the second quarter, compared to a profit last year, hurt primarily by hefty amortization expenses. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. Looking ahead, the company raised its adjusted earnings and revenue outlook for the full-year 2020.
Follow RTT